| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/22/2001 | CA2383923A1 Method and apparatus for producing a sterile fluid |
| 03/22/2001 | CA2383565A1 Rxr modulators with improved pharmacologic profile |
| 03/22/2001 | CA2383405A1 Process for making aqueous coated beadlets |
| 03/22/2001 | CA2383402A1 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 03/22/2001 | CA2383360A1 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 03/22/2001 | CA2383177A1 Human g-protein coupled receptor |
| 03/22/2001 | CA2383026A1 Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| 03/22/2001 | CA2383003A1 Single stranded oligonucleotides, probes, primers and method for detecting spirochetes |
| 03/22/2001 | CA2382908A1 Composition for ivf |
| 03/22/2001 | CA2382683A1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-¬4-(2-amin-1-yl-ethoxy)-benzyl|-1h-indol-5-ols |
| 03/22/2001 | CA2382633A1 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | CA2382008A1 Stable carotene-xanthophyll beadlet compositions and methods of use |
| 03/22/2001 | CA2381252A1 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 03/22/2001 | CA2381078A1 Method of potentiating chemotherapy and treating solid tumors |
| 03/22/2001 | CA2381066A1 Polymorphisms in the human hpxr gene and their use in diagnostic and therapeutic applications |
| 03/22/2001 | CA2381006A1 Antisense modulation of transforming growth factor-.beta. expression |
| 03/22/2001 | CA2379541A1 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 03/22/2001 | CA2377221A1 Hydroxyalkanoyl aminolactams and related structures as inhibitors of a.beta. protein production |
| 03/22/2001 | CA2350675A1 Galenic formulations fast disintegrating in the mouth and method for preparing same |
| 03/21/2001 | EP1085096A2 Preparation of high trehalose content product |
| 03/21/2001 | EP1085089A2 Human cyclic nucleotide phosphodiesterase |
| 03/21/2001 | EP1085014A1 1,5-benzodiazepine derivatives |
| 03/21/2001 | EP1085011A1 Novel polyamine analogues as therapeutic and diagnostic agents |
| 03/21/2001 | EP1084726A2 Metered dose inhaler for fluticasone propionate |
| 03/21/2001 | EP1084711A1 Remedies for itching containing pgd 2? antagonists |
| 03/21/2001 | EP1084710A1 Remedies for male sterility |
| 03/21/2001 | EP1084706A2 Use of simethicone to treat ulcerative colitis |
| 03/21/2001 | EP1084705A2 Method for lowering blood glucose levels in mammals |
| 03/21/2001 | EP1084704A1 Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia |
| 03/21/2001 | EP1084701A1 O/W-emulsion comprising one or several bioquinones and an elevated amount of glycerine |
| 03/21/2001 | EP1084693A1 $g(a)-HYDROXY FATTY ACID DERIVATIVES AND COMPOSITION FOR EXTERNAL USE CONTAINING THE SAME |
| 03/21/2001 | EP1084575A1 Time and location-driven personalized tv |
| 03/21/2001 | EP1084569A2 Pharmaceutical combinations for compensating for a testosterone deficiency in men while simultaneously protecting the prostate |
| 03/21/2001 | EP1084325A1 Arrangement for the removal of cuttings and gas arising from drilling operations |
| 03/21/2001 | EP1084274A1 Acrp30r2, a homolog of acrp30 (30 kd adipocyte complement-related protein) |
| 03/21/2001 | EP1084255A1 Tankyrase, a trf1 binding protein |
| 03/21/2001 | EP1084252A1 Nucleic acid vaccines for prevention of flavivirus infection |
| 03/21/2001 | EP1084237A1 Stabilized transient gene expression |
| 03/21/2001 | EP1084214A1 Contaminant reduced marine oil |
| 03/21/2001 | EP1084137A1 Peptide inhibitors of hepatitis c virus ns3 protease |
| 03/21/2001 | EP1084129A1 Cyclic boroproline compounds |
| 03/21/2001 | EP1084125A1 Condensed thienopyrimidines with phosphodiesterase-v inhibiting action |
| 03/21/2001 | EP1084124A1 Benzothiazolythiomethyl carbapenem antibacterial |
| 03/21/2001 | EP1084123A1 Novel asymmetrically substituted xanthine derivatives, method for producing them and their use as medicaments with an adenosine-antagonistic effect |
| 03/21/2001 | EP1084122A1 Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity |
| 03/21/2001 | EP1084120A1 Cinnamoyl distamycin analogous derivatives, process for their preparation, and their use as antitumor agents |
| 03/21/2001 | EP1084119A1 Aromatic amine derivatives as pharmaceutical agents |
| 03/21/2001 | EP1084118A1 Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4- 4-(4pyridyl) benzoyl] piperazine |
| 03/21/2001 | EP1084114A1 Isothiazole derivatives useful as anticancer agents |
| 03/21/2001 | EP1084113A1 A process for the preparation of macrocyclic metalloprotease inhibitors |
| 03/21/2001 | EP1084110A1 Quinolones used as mrs inhibitors and bactericides |
| 03/21/2001 | EP1084109A1 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |
| 03/21/2001 | EP1084108A1 Spla 2? inhibitor compounds for treatment of disease |
| 03/21/2001 | EP1084107A1 Aza-heterocyclic compounds used to treat neurological disorders and hair loss |
| 03/21/2001 | EP1084106A1 N-linked sulfonamides of heterocyclic carboxylic acids or carboxylic acid isosteres |
| 03/21/2001 | EP1084105A1 Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment |
| 03/21/2001 | EP1084104A1 Nitric oxide synthase inhibitors |
| 03/21/2001 | EP1084103A1 New 3-aryl-2-hydroxypropionic acid derivative (i) |
| 03/21/2001 | EP1084102A1 New 3-aryl propionic acid derivatives and analogs |
| 03/21/2001 | EP1084101A1 New 3-aryl-2-hydroxypropionic acid derivative iii |
| 03/21/2001 | EP1084098A1 Inhibitors of the anandamide transporter as analgesic agents |
| 03/21/2001 | EP1083932A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine |
| 03/21/2001 | EP1083931A1 Stabilization of compositions containing ace inhibitors using magnesium oxide |
| 03/21/2001 | EP1083929A2 The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 03/21/2001 | EP1083927A1 HUMAN MINOR VAULT PROTEIN p193 |
| 03/21/2001 | EP1083921A1 Novel leukotriene receptor antagonists and their uses |
| 03/21/2001 | EP1083920A1 Novel antibacterial compounds |
| 03/21/2001 | EP1083919A1 Novel antiviral compounds |
| 03/21/2001 | EP1083918A1 Novel therapeutic agents that modulate 5-ht receptors |
| 03/21/2001 | EP1083917A1 Novel analgesic agents |
| 03/21/2001 | EP1083914A1 Treatment of arthritis and other similar conditions |
| 03/21/2001 | EP1083913A1 Monoamine oxidase (mao) inhibitors and uses thereof |
| 03/21/2001 | EP1083910A1 nrdE |
| 03/21/2001 | EP1083906A1 Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue |
| 03/21/2001 | EP1083905A2 Selective estrogen receptor modulator in combination with dehydroepiandrosterone (dhea) or analogues |
| 03/21/2001 | EP1083904A2 Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol |
| 03/21/2001 | EP1083903A1 Bridged indenopyrrolocarbazoles |
| 03/21/2001 | EP1083902A1 Novel galenic formulations of meloxicam for oral administration |
| 03/21/2001 | EP1083901A1 Efavirenz compressed tablet formulation |
| 03/21/2001 | EP1083900A2 Topical administration of oxazolidinones for transdermal delivery |
| 03/21/2001 | EP1083899A1 METHOD OF ENHANCING LYSOSOMAL $g(a)-GALACTOSIDASE A |
| 03/21/2001 | EP1083898A1 Novel use of hiv protease inhibiting compounds |
| 03/21/2001 | EP1083897A1 Hiv integrase inhibitors |
| 03/21/2001 | EP1083896A1 Use of neomycin for treating angiogenesis-related diseases |
| 03/21/2001 | EP1083895A2 Use of sclareol-like or scareolide-like compounds for the treatment of microbial infections |
| 03/21/2001 | EP1083894A1 MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE |
| 03/21/2001 | EP1083893A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the d 1? receptors |
| 03/21/2001 | EP1083892A1 Topical application of muscarinic analgesic drugs such as neostigmine |
| 03/21/2001 | EP1083891A1 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 03/21/2001 | EP1083890A1 N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use |
| 03/21/2001 | EP1083889A2 Method for treating neurodegenerative disorders |
| 03/21/2001 | EP1083888A1 MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS |
| 03/21/2001 | EP1083887A2 Pharmaceutical compositions for ulcer |
| 03/21/2001 | EP1083886A1 Drug delivery system comprising a tightly compacted solid medicament stock |
| 03/21/2001 | EP1083885A1 Delavirdine tablet formulation |
| 03/21/2001 | EP1083881A2 Liposome composition and method for administering a quinolone |
| 03/21/2001 | EP1083880A1 Stable gel mixture in the form of a mixture of oleogel and aqueous gel |
| 03/21/2001 | EP1083879A1 Methods and devices for providing prolonged drug therapy |
| 03/21/2001 | EP1083877A1 N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses |
| 03/21/2001 | EP1083876A1 Small molecule sulfonamide hair growth compositions and uses |